Cargando…
Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study
Background: Both sodium glucose cotransporter 2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have cardiovascular protective effects in patients with type 2 diabetes mellitus. However, the comparative risk of GLP-1RA versus SGLT-2i for major adverse limb events remains...
Autores principales: | Lee, Yen-Chieh, Dong, Yaa-Hui, Yang, Wei-Shun, Wu, Li-Chiu, Lin, Jou-Wei, Chang, Chia-Hsuin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513310/ https://www.ncbi.nlm.nih.gov/pubmed/36176438 http://dx.doi.org/10.3389/fphar.2022.869804 |
Ejemplares similares
-
Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
por: Lin, Tzu-Yi, et al.
Publicado: (2023) -
Evidence‐based comparison of glucagon‐like peptide receptor agonists and sodium–glucose cotransporter 2 inhibitors
por: Watada, Hirotaka
Publicado: (2019) -
Patients’ Preferences for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
por: Banjara, Bidur, et al.
Publicado: (2022) -
Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM
por: McKee, Alexis, et al.
Publicado: (2020) -
Effects of glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors on major adverse cardiovascular events in type 2 diabetes by race, ethnicity, and region: A meta-analysis
por: Qiu, Mei, et al.
Publicado: (2020)